EP1560595A4 - Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain - Google Patents

Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain

Info

Publication number
EP1560595A4
EP1560595A4 EP02784189A EP02784189A EP1560595A4 EP 1560595 A4 EP1560595 A4 EP 1560595A4 EP 02784189 A EP02784189 A EP 02784189A EP 02784189 A EP02784189 A EP 02784189A EP 1560595 A4 EP1560595 A4 EP 1560595A4
Authority
EP
European Patent Office
Prior art keywords
fab fragments
neutralizing activity
antibody fab
human antibody
fully human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02784189A
Other languages
German (de)
English (en)
Other versions
EP1560595A2 (fr
Inventor
Rajendra V Deshpande
Mei-Mei Tsai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority claimed from PCT/US2002/033556 external-priority patent/WO2004046306A2/fr
Publication of EP1560595A2 publication Critical patent/EP1560595A2/fr
Publication of EP1560595A4 publication Critical patent/EP1560595A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP02784189A 2002-10-17 2002-10-17 Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain Withdrawn EP1560595A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/033556 WO2004046306A2 (fr) 2001-10-05 2002-10-17 Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain

Publications (2)

Publication Number Publication Date
EP1560595A2 EP1560595A2 (fr) 2005-08-10
EP1560595A4 true EP1560595A4 (fr) 2005-12-28

Family

ID=34374685

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02784189A Withdrawn EP1560595A4 (fr) 2002-10-17 2002-10-17 Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain

Country Status (5)

Country Link
EP (1) EP1560595A4 (fr)
JP (1) JP2006502739A (fr)
AU (1) AU2002347978B2 (fr)
CA (1) CA2502668C (fr)
MX (1) MXPA05003949A (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002005A1 (fr) * 1989-08-11 1991-02-21 Adolfo Turano Anticorps a interferons anti-gamma humains naturels, detectes et purifies par des peptides synthetiques
WO2000032634A1 (fr) * 1998-12-01 2000-06-08 Protein Design Labs, Inc. Anticorps anti-interferon gamma humanises

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009055A2 (fr) * 1997-08-18 1999-02-25 Innogenetics N.V. Molecules de fixation d'interferon-gamma permettant de traiter des chocs septiques, la cachexie, des troubles immunitaires et des problemes dermatologiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002005A1 (fr) * 1989-08-11 1991-02-21 Adolfo Turano Anticorps a interferons anti-gamma humains naturels, detectes et purifies par des peptides synthetiques
WO2000032634A1 (fr) * 1998-12-01 2000-06-08 Protein Design Labs, Inc. Anticorps anti-interferon gamma humanises

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FIORENTINI S ET AL: "A partially humanized monoclonal antibody to human IFN-gamma inhibits cytokine effects both in vitro and in vivo", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 55, no. 3, March 2002 (2002-03-01), pages 284 - 292, XP002347393, ISSN: 0300-9475 *
GREEN L L: "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 11 - 23, XP004187631, ISSN: 0022-1759 *
GRIFFITHS A D ET AL: "ISOLATION OF HIGH AFFINITY HUMAN ANTIBODIES DIRECTLY FROM LARGE SYNTHETIC REPERTOIRES", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 13, no. 14, 15 July 1994 (1994-07-15), pages 3245 - 3260, XP000455240, ISSN: 0261-4189 *
MAYNARD J ET AL: "ANTIBODY ENGINEERING", ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, ANNUAL REVIEW INCO., PALO ALTO, CA, US, vol. 2, 2000, pages 339 - 376, XP009039750 *
See also references of WO2004046306A2 *

Also Published As

Publication number Publication date
MXPA05003949A (es) 2005-06-17
CA2502668C (fr) 2013-07-30
JP2006502739A (ja) 2006-01-26
CA2502668A1 (fr) 2004-06-03
EP1560595A2 (fr) 2005-08-10
AU2002347978B2 (en) 2009-10-08
AU2002347978A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
IL165256A0 (en) Neutralizing human anti-igfr antibody
TWI367102B (en) Therapeutic human anti-il-1r1 monoclonal antibody
EP1572131A4 (fr) Therapie fondee sur les anticorps
IL168304A (en) Human monoclonal antibodies against cd25
EP1494714A4 (fr) Anticorps humain neutralisant anti opgl utilises en tant qu'inhibiteurs de chemin d'opgl
AU2003295411A8 (en) Human monoclonal antibodies to heparanase
EP1741783A4 (fr) Anticorps de beta peptide antiamyloïde humain et fragment anticorps de celui-ci
EP1471938A4 (fr) Anticorps monoclonaux humains contre cd30
AU2003290685A8 (en) Active fasteners
AU2003241291A8 (en) Vascularized human skin equivalent
IL172511A0 (en) Specific human antibodies
EP1621616A4 (fr) Anticorps humain d'interleukine-18 antihumaine, fragment de celle-ci et procede d'utilisation correspondant
EP1532173A4 (fr) Analyse de proteines
AU2003226899A8 (en) Human diabetes-mediating proteins
AU2003277832A8 (en) Humanized tissue factor antibodies
EP1687029A4 (fr) Neutralisation d'anticorps humains par rapport a une toxine d'anthrax generes par une technologie de concordance
AU2003287016A8 (en) Human sarcoma-associated antigens
PL377592A1 (pl) Fragmenty w pełni ludzkiego przeciwciała Fab o działaniu neutralizującym aktywność ludzkiego interferonu-gamma
EP1560595A4 (fr) Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain
EP1539957A4 (fr) Nouvelles methodes de diagnostic et de therapie et reactifs correspondants
EP1490188A4 (fr) Dispositif d'emboutissage
AU2003236346A1 (en) Monoclonal antibody neutralizing megsin
AU2002100580A4 (en) Maths mat abacus
AU2003229752A1 (en) Human rhomboid-related protein
PL352665A1 (en) Therapeutic underwear

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050509

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 16/24 B

Ipc: 7C 07K 14/57 B

Ipc: 7A 61K 39/395 B

Ipc: 7C 07K 16/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20051110

17Q First examination report despatched

Effective date: 20060112

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101115